The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 25, 2023
Filed:
Feb. 04, 2022
Innovative Cellular Therapeutics Holdings, Ltd., George Town, KY;
Innovative Cellular Therapeutics, Inc., Rockville, MD (US);
Yang Li, Shanghai, CN;
Zhiyuan Cao, Shanghai, CN;
Wei Ding, Shanghai, CN;
Xianyang Jiang, Shanghai, CN;
Chengfei Pu, Shanghai, CN;
Le Tian, Rockville, MD (US);
Christopher Ballas, Rockville, MD (US);
Zhao Wu, Shanghai, CN;
Lei Xiao, Rockville, MD (US);
Innovative Cellular Therapeutics Holdings, Ltd., George Town, KY;
Innovative Cellular Therapeutics, Inc., Rockville, MD (US);
Abstract
The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFNγ.